Satoshi Yasumura
University of Pittsburgh
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Satoshi Yasumura.
Cancer Immunology, Immunotherapy | 1994
Satoshi Yasumura; Andrew A. Amoscato; Hideki Hirabayashi; Wen-chang Lin; Theresa L. Whiteside
The supernatant of a cell line of squamous cell carcinoma of the head and neck (SCCHN), PCI-50, was previously shown to induce activation, promote proliferation and increase antitumor cytotoxicity of freshly purified human natural killer (NK) cells and CD4+ T lymphocytes [Arch Otolaryngol Head Neck Surg (1994) in press]. This supernatant was found also to promote the growth of a variety of hematopoietic cell lines, including Jurkat, THP-1, K562, NK-92 or Epstein-Barr-virus-transformed B cell lines. The Jurkat cell line was selected as a reporter cell in an 18-h proliferation assay established to measure the growth-promoting activity of PCI-50 supernatant. The presence of soluble tumor-derived factors able to induce proliferation of Jurkat cells was demonstrated in the supernatant produced by several other SCCHN cell lines but not in that produced by a gastric cancer cell line (HR) or renal cell carcinoma line (5117G8). The growth-promoting PCI-50 supernatant was shown to contain 28±0.5 pg/ml interleukin-6, (IL-6) in vitro but was negative for interferon γ, IL-1, IL-2, IL-4, tumor necrosis factor α, granulocyte/macrophage-colony-stimulating factor and IL-12. The addition of any of these recombinant cytokines to Jurkat cell cultures did not significantly promote growth, while PCI-50 supernatant was consistently growth-stimulatory. This supernatant neither enhanced intracellular Ca2+ concentration in Jurkat cells nor induced up-regulation of activation antigens on the cell surface, although it supported growth of Jurkat cells in the absence of IL-2. The growth-promoting activity in the PCI-50 supernatant was acid-labile at pH 2 for 4 h, heat-resistant at 96 °C for 1 h and sensitive to treatments with trypsin and pepsin. Preincubation of the PCI-50 producer cells with tunicamycin or cyclohexamide reduced the level of growth-promoting activity in the supernatant. A partial purification of this activity was achieved using Amicon filtration, chromatography on concanavalin-A-Sepharose and then a hydroxyapatite column and high-pressure liquid chromatography gel filtration. The partially purified glycoprotein had a molecular mass of 50–70 kDa, as detemined by gel filtration.
Cancer Research | 1993
Satoshi Yasumura; Hideki Hirabayashi; Donald R. Schwartz; John Toso; Jonas T. Johnson; Ronald B. Herberman; Theresa L. Whiteside
Cancer Research | 1992
Eckhart Weidmann; Manuela Sacchi; S. Plaisance; Dae Seog Heo; Satoshi Yasumura; Wen-chang Lin; Jonas T. Johnson; Ronald B. Herberman; Bruno Azzarone; Theresa L. Whiteside
International Journal of Cancer | 1994
Satoshi Yasumura; Wen-chang Lin; Eckhart Weidmann; Patricia A. Hebda; Theresa L. Whiteside
Cancer Research | 1994
Satoshi Yasumura; Wen-chang Lin; Hideki Hirabayashi; Nikola L. Vujanovic; Ronald B. Herberman; Theresa L. Whiteside
Clinical Cancer Research | 1996
Jeffrey N. Myers; Satoshi Yasumura; Yoshinori Suminami; Hideki Hirabayashi; Wen-chang Lin; Jonas T. Johnson; Michael T. Lotze; Theresa L. Whiteside
Cancer Research | 1993
Eckhart Weidmann; Theodore F. Logan; Satoshi Yasumura; John M. Kirkwood; Massimo Trucco; Theresa L. Whiteside
International Journal of Cancer | 1994
Satoshi Yasumura; Eckhart Weidmann; Hideki Hirabayashi; Jonas T. Johnson; Ronald B. Herberman; Theresa L. Whiteside
Cellular Immunology | 1997
Kazuhiko Okada; Satoshi Yasumura; Ingrid Müller-Fleckenstein; Bernhard Fleckenstein; Sohel Talib; Ursula Koldovsky; Theresa L. Whiteside
International Journal of Cancer | 1995
Myung-Whun Sung; Satoshi Yasumura; Jonas T. Johnson; Guus A.M.S. van Dongen; Theresa L. Whitesidi